Evaluation of potential tumor markers that may predict neoadjuvant treatment efficiency in rectal cancer

Arslan F. D., Kocak A., Aydin C., Pala E. E., Oncel D., Diniz G., ...More

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.46, no.4, pp.445-454, 2021 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1515/tjb-2020-0507
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Food Science & Technology Abstracts, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.445-454
  • Keywords: Beclin 1, carbonic anhydrase-9, hypoxia-inducible factor-1 alpha, neoadjuvant treatment, rectal cancer, Survivin, CARBONIC-ANHYDRASE, COLORECTAL-CANCER, CHEMORADIATION THERAPY, BECLIN 1, EXPRESSION, HYPOXIA, AUTOPHAGY, SURVIVIN, CHEMORADIOTHERAPY, CELLS
  • Dokuz Eylül University Affiliated: Yes


Objectives: The recurrence of rectal cancer or its resistance to neoadjuvant treatment develops due to the adaptation to hypoxia, apoptosis or autophagy. Survivin, one of the inhibitors of apoptosis; Beclin 1, which is a positive regulator in the autophagy pathway; and hypoxia-inducible factor-1 alpha (HIF-1 alpha) and carbonic anhydrase-9 (CA9), which are associated with tumor tissue hypoxia, may be related to resistance to treatment. Our aim was to evaluate the potential tumor markers that may help to monitor the response to neoadjuvant treatment in locally advanced rectal cancer (RC).